Disease · MONDO_0007947

Marfan syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Marfan syndrome. Diseases, record MONDO_0007947. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007947

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Marfan syndrome; Open Targets
Open Targets ID: MONDO_0007947; Open Targets
Other names: MFS, MFS1, Marfan syndrome type 1, Marfan's syndrome; Open Targets
Disease Ontology: DOID:14323; Disease Ontology
MeSH: D008382; MeSH
NCI Thesaurus: C34807; NCI Thesaurus
Orphanet: ORPHA:284963; Orphanet
Orphanet: ORPHA:558; Orphanet
Highest stage of its drugs: Phase 3, for 5 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LOSARTAN	CHEMBL191	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ATENOLOL	CHEMBL24	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NEBIVOLOL	CHEMBL434394	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PERINDOPRIL	CHEMBL1581	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IRBESARTAN	CHEMBL1513	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	2	Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets
REN	Renin	1	Renin inhibitor	Phase 3	https://conductscience.org/library/genes/5972	Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00429364	Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome	Phase 3	608	2015-04-01	Marfan Syndrome	ATENOLOL, LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00723801	Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome	Phase 3	40	2014-09-01	Marfan Syndrome	LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT01715207	Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS	Phase 3	30	2017-05-04	Marfan Syndrome	ALISKIREN	Its record names the disease	ClinicalTrials.gov
NCT00763893	Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome	Phase 3	303		Marfan Syndrome	LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00683124	Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients	Phase 3	291		Marfan Syndrome	LOSARTAN, NEBIVOLOL	Its record names the disease	ClinicalTrials.gov
NCT01949233	The Oxford Marfan Trial	Phase 2	56		Marfan Syndrome	DOXYCYCLINE, IRBESARTAN	Its record names the disease	ClinicalTrials.gov
NCT00485368	Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome	Phase 3	17		Marfan Syndrome	PERINDOPRIL	Its record names the disease	ClinicalTrials.gov
NCT00593710	Losartan Versus Atenolol for the Treatment of Marfan Syndrome	Phase 2	17		Marfan Syndrome	ATENOLOL, LOSARTAN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Atenolol vs Losartan: Number of Death.	0 of 303	1 of 305	608	NCT00429364	Trial comparisons
Atenolol vs Losartan: Number of Participants With Aortic-root Surgery.	10 of 303	18 of 305	608	NCT00429364	Trial comparisons
Atenolol vs Losartan: Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.	10 of 303	19 of 305	608	NCT00429364	Trial comparisons
Atenolol vs Losartan: Number of Participants With Aortic Dissection.	0 of 303	2 of 305	608	NCT00429364	Trial comparisons
Atenolol vs Losartan: serious adverse events	27 of 303	33 of 305	608	NCT00429364	Trial comparisons
Subjects Randomized to Atenolol vs Subjects Randomized to Losartan: serious adverse events	0 of 20	0 of 20	40	NCT00723801	Trial comparisons
Atenolol & Aliskiren vs Atenolol: serious adverse events	2 of 14	0 of 14	28	NCT01715207	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25935877	RESULT	1	PubMed
20619242	RESULT	1	PubMed
17911499	RESULT	2	PubMed
17188619	RESULT	1	PubMed
16601194	RESULT	1	PubMed
29948025	DERIVED	1	PubMed
26052700	DERIVED	1	PubMed
25465809	DERIVED	1	PubMed
25405392	DERIVED	1	PubMed
23622922	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007947

GET https://conductscience.org/api/diseases/v1/MONDO_0007947/drugs

API reference For AI assistants